The Spanish Group for Research in Gynecological Cancer (GEICO) celebrates its 25th anniversary, reaffirming its commitment to advancing gynecological cancer research.
Within the framework of the XI GEICO Symposium, the Spanish Group for Research in Gynecological Cancer—founded in 1999—will celebrate a major milestone: 25 years dedicated to excellence in gynecologic oncology research.
Over the past quarter century, GEICO has become a cornerstone in the training of oncology specialists and a leader in clinical research that has improved the treatment of ovarian, endometrial, and cervical cancers. Through its ongoing work, GEICO has established itself as a national and international reference in innovative therapies for gynecological malignancies.
25 years of progress in cancer research
“The identification of biomarkers and the incorporation of targeted therapies have allowed us to personalize treatments, improving outcomes and prognosis for our patients,” stated Dr. Antonio González-Martín, President of GEICO. Throughout these years, GEICO has played a pivotal role in the design and execution of clinical trials with new therapies, focusing on biomarker-driven approaches that enable personalized treatment strategies tailored to each patient’s characteristics. “Some of these studies have not only improved cure rates but have also changed the standard of care,” added Dr. González-Martín.
Global collaboration and a forward-looking commitment.
GEICO’s impact extends far beyond Spain’s borders, thanks to its active participation in international research networks such as ENGOT (European Network for Gynaecological Oncological Trial Groups) and GCIG (Gynecologic Cancer InterGroup). These collaborations have enabled GEICO to contribute to high-impact, multicenter clinical trials that are shaping the global landscape of gynecologic oncology.
Its members are regularly featured as speakers and lead authors at major international oncology congresses, strengthening GEICO’s role in advancing scientific discussion and the development of new therapeutic strategies.
Beyond clinical trials: a comprehensive vision.
GEICO’s mission goes beyond clinical research. The group also plays a key role in medical education, scientific exchange, and the continuous training of gynecologic oncology specialists.
Over the years, GEICO has organized high-level symposia and training programs designed to make the latest scientific advances accessible to all professionals involved in the care and management of gynecologic cancer patients.
GEICO also leads and collaborates in the development of national and international clinical guidelines that serve as benchmarks for the management of gynecologic malignancies. This comprehensive approach ensures that both clinicians and patients benefit from the latest scientific and therapeutic innovations.
About GEICO
The Spanish Group for Research in Gynecological Cancer (GEICO) is a non-profit scientific organization dedicated to promoting research and advancing the treatment of gynecologic malignancies.
Since its foundation in 1999, GEICO has become a national leader in oncologic research, driving high-impact clinical studies and fostering scientific collaboration.
Its mission is built on three fundamental pillars: research excellence, specialist training, and a commitment to improving patients’ quality of life.
GEICO’s objectives include developing and coordinating clinical trials, generating innovative scientific knowledge, and promoting continuous education in gynecologic oncology—all with the purpose of providing patients with the best possible therapeutic options.
With its sights set on the future, GEICO remains committed to innovation and progress, working to improve patient outcomes and survival rates. Here’s to the next 25 years.
